GLP-1 and incretin compared

Retatrutide vs tirzepatide

An investigational triple agonist and an approved dual agonist, side by side.

Retatrutide is an investigational agonist of the GIP, GLP-1 and glucagon receptors, and tirzepatide acts on the GIP and GLP-1 receptors.1,2,3 The phase 1b report gives retatrutide's half-life as approximately 6 days, and the Mounjaro label gives tirzepatide's as approximately 5 days.4,3

Tirzepatide has been approved in the US since 2022, while the FDA says retatrutide is not a component of an FDA-approved drug.3,5 The weight figures below come from separate trials. A 2026 review, with evidence to 11 September 2026, reports no completed head-to-head trial of retatrutide and names TRIUMPH-5, against tirzepatide, as a randomised comparison that could support one.6,7

FactRetatrutideTirzepatide
What it isAn investigational agonist of the GIP, GLP-1 and glucagon receptors1,2A once weekly GIP and GLP-1 receptor agonist made by Eli Lilly and Company3
How it comesOnce-weekly subcutaneous injection in trials; not a component of an FDA-approved drug6,5Mounjaro pens and vials from 2.5 mg/0.5 mL to 15 mg/0.5 mL, injected under the skin once weekly3
Half-life
  • Approximately 6 days in an early report in people with diabetes4
  • 134 to 165 hours in the first-in-human study, per a recent review2
  • Approximately 5 days on the Mounjaro label3
  • Mean 116.7 hours in an early human study10
Doses and results
  • Mid-stage trial, 338 adults: 1, 4, 8 or 12 mg once weekly; no dose is approved1,5
  • Late-stage trial, 2339 adults on 4, 9 or 12 mg or placebo: weight -17.6%, -23.7% and -25.0% at 80 weeks against -3.9% on placebo6
  • Mounjaro label: start at 2.5 mg, up to 15 mg once weekly3
  • Zepbound label: 5, 10 or 15 mg once weekly for weight reduction11
  • Placebo-controlled trial, 2539 adults on 5, 10 or 15 mg or placebo: weight -15.0%, -19.5% and -20.9% at 72 weeks against -3.1% on placebo7
StatusNot a component of an FDA-approved drug, and not approved by the TGA or a comparable international regulator5,9First approved in the US in 2022, as Mounjaro; also approved as Zepbound3,11

Get the app

Contents5
  1. 1How they differ
  2. 2Logged in Milligram
  3. 3What is not known
  4. 4References
  5. 5Related pages

Last reviewed . Sources are listed below.

How they differ

Retatrutide adds the glucagon receptor to the two receptors tirzepatide acts on, and in obese mice the authors report that weight loss was augmented by glucagon receptor-mediated increases in energy expenditure.8 A 2026 review states that improvement in blood sugar control supports the net efficacy of the combined molecule rather than a separately quantified benefit for each receptor.2

Gastrointestinal events were the most common adverse events in both the retatrutide and tirzepatide trials.6,7 Eli Lilly funded the phase 3 retatrutide trial and supported the tirzepatide trial in the table.6,7

Logged in Milligram

  • Retatrutide: 49% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
  • Tirzepatide: 5% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

A 2026 review states that retatrutide's indications, contraindications and prescribing instructions require regulatory review, and that rare events, pregnancy exposure and long-term effects need larger datasets and dedicated follow-up.2 The TGA states that any retatrutide product accessed outside of clinical trials could be a counterfeit product.9

In a boxed warning, the Mounjaro label states that tirzepatide causes thyroid C-cell tumors in rats, that it is unknown whether Mounjaro does in humans, and that Mounjaro is contraindicated with a personal or family history of medullary thyroid carcinoma or with MEN 2.3

References

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Peer-reviewed paper (phase 2), 2023. PMID 37366315
  2. Mateescu DM, et al. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence. Peer-reviewed narrative review, full text (evidence to 11 September 2026), 2026. PMC13708278
  3. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing information, revised August 2026. US label (DailyMed), 2026. DailyMed label
  4. Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Peer-reviewed paper (phase 1b), 2022. PMID 36354040
  5. US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Regulator web page, 2026. fda.gov
  6. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Peer-reviewed paper (phase 3), 2026. PMID 42814954
  7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. Phase 3 randomised trial, 2022. PMID 35658024
  8. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Peer-reviewed paper (preclinical and phase 1), 2022. PMID 35985340
  9. Therapeutic Goods Administration (Australia). TGA tests counterfeit retatrutide product following serious adverse event report. Regulator web page, 2026. tga.gov.au
  10. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Phase 1 study and preclinical paper, 2018. PMC6308032
  11. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Prescribing information, revised August 2026. US label (DailyMed), 2026. DailyMed label